$21.89
2.58% yesterday
Nasdaq, Oct 23, 10:12 pm CET
ISIN
US8036071004
Symbol
SRPT

Sarepta Therapeutics, Inc. Stock price

$21.89
+3.96 22.09% 1M
-37.60 63.20% 6M
-99.70 82.00% YTD
-107.99 83.15% 1Y
-88.71 80.21% 3Y
-115.84 84.11% 5Y
-3.09 12.37% 10Y
+2.51 12.95% 20Y
Nasdaq, Closing price Thu, Oct 23 2025
-0.58 2.58%

Key metrics

Basic
Market capitalization
$2.1b
Enterprise Value
$2.5b
Net debt
$339.3m
Cash
$800.1m
Shares outstanding
97.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.9 | 1.0
EV/Sales
1.0 | 1.2
EV/FCF
negative
P/B
1.6
Financial Health
Equity Ratio
38.6%
Return on Equity
15.4%
ROCE
0.0%
ROIC
-0.1%
Debt/Equity
0.8
Financials (TTM | estimate)
Revenue
$2.5b | $2.1b
EBITDA
$1.5m | $-320.7m
EBIT
$-932.0k | $-440.2m
Net Income
$-58.0m | $-438.3m
Free Cash Flow
$-454.0m
Growth (TTM | estimate)
Revenue
64.9% | 9.4%
EBITDA
-96.2% | -245.4%
EBIT
-102.5% | -301.8%
Net Income
-222.5% | -286.3%
Free Cash Flow
14.0%
Margin (TTM | estimate)
Gross
79.3%
EBITDA
0.1% | -15.4%
EBIT
0.0%
Net
-2.3% | -21.1%
Free Cash Flow
-18.3%
More
EPS
$-0.5
FCF per Share
$-4.6
Short interest
21.7%
Employees
1k
Rev per Employee
$1.4m
Show more

Is Sarepta Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,021 stocks worldwide.

Sarepta Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

35 Analysts have issued a Sarepta Therapeutics, Inc. forecast:

13x Buy
37%
16x Hold
46%
6x Sell
17%

Analyst Opinions

35 Analysts have issued a Sarepta Therapeutics, Inc. forecast:

Buy
37%
Hold
46%
Sell
17%

Financial data from Sarepta Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
2,482 2,482
65% 65%
100%
- Direct Costs 514 514
192% 192%
21%
1,967 1,967
48% 48%
79%
- Selling and Administrative Expenses 564 564
9% 9%
23%
- Research and Development Expense 1,402 1,402
82% 82%
57%
1.54 1.54
96% 96%
0%
- Depreciation and Amortization 2.47 2.47
4% 4%
0%
EBIT (Operating Income) EBIT -0.93 -0.93
102% 102%
0%
Net Profit -58 -58
222% 222%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about Sarepta Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sarepta Therapeutics, Inc. Stock News

Neutral
PRNewsWire
one day ago
Funds seek to provide 200% long exposure on a variety of industry leaders NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for sophisticated investors and professional traders, today launched nine new single stock leveraged ETFs, seven of which are first-to-market strategies. The funds, all listed on Cboe, seek to deliver twice (200%) the daily performance of a s...
Positive
Seeking Alpha
14 days ago
Sarepta Therapeutics is showing signs of recovery, driven by its robust pipeline and recent revenue growth, despite past clinical setbacks. SRPT's near-term catalyst is SRP-9003, a gene therapy for Limb-Girdle Muscular Dystrophy, with pivotal Phase 3 data expected in late 2025 or early 2026. Valuation remains attractive, with SRPT trading at a discount to peers and holding a strong cash positio...
Neutral
Business Wire
21 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the 30th Annual Congress of the World Muscle Society (WMS) 2025 Congress, taking place Oct. 7-11, 2025, in Vienna, Austria. Sarepta presentations will include results from several studies in the delandistrogene moxeparvovec clinical development...
More Sarepta Therapeutics, Inc. News

Company Profile

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Head office United States
CEO Douglas Ingram
Employees 1,372
Founded 1980
Website www.sarepta.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today